Determining emphysema in adult patients with COPD-bronchiectasis overlap using a novel spirometric parameter: area under the forced expiratory flow-volume loop. (2nd August 2020)

• Record Type: Journal Article
• Authors: Satici, Celal; Arpinar Yigitbas, Burcu; Demirkol, Mustafa Asim; Kosar,
• Is Part Of: Expert review of respiratory medicine. Volume 14:Number 8(2020)
• Page Start: 839
• Page End: 844
• Publication Date: 2020-08-02
• Subjects: Emphysema -- chronic obstructive pulmonary disease -- bronchiectasis -- area under flow–volume curve -- COPD bronchiectasis overlap; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1080/17476348.2020.1766972
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Background: Defining the optimal therapeutic approach in patients with chronic obstructive pulmonary disease (COPD) bronchiectasis overlap (CBO) is challenging. The presence of emphysema suggests that COPD is the primary problem and it impacts therapeutic decision making. Research design and methods: We hypothesized that the AreaFE% performance will be reliable in diagnosing the presence of emphysema such that serial CT scanning may not be needed. In this retrospective chart review study, we included 113 CBO patients (52 having emphysema, 61 not having emphysema). We compared these two groups according to conventional spirometric parameters and AreaFE% values. Results: 54% of all patients were female and mean age was 58 years.FEV1%, FEV1/FVC and AreaFE% were found to be significantly lower in patients with emphysema. 12% is the cutoff value for AreaFE% in determining emphysema with 73% sensitivity, 75% specificity, and 72% diagnostic accuracy (AUC: 0.82) and it provides superior estimation than conventional parameters. Conclusions: We found that AreaFE% is more suitable for determining the presence of emphysema than conventional spirometric parameters in CBO patients. This novel parameter may be helpful instead of scanning thorax CT to indicate the presence of emphysema and manage treatment in the follow-up of CBO patients.